Paperonium

← Back to the plain-language case

Abstract reports 18 PDX models for the co-clinical trial; the paper's data contain 15

Cancer Res (2022) · doi:10.1158/0008-5472.CAN-22-0198 · PMC9478530

Summary

The abstract says the combination of MEK and CDK4/6 inhibition was tested "across 18 PDX models" and that 60% of tumors regressed, meeting the co-clinical trial's primary endpoint. Every other count in the paper gives 15 models. The Results subgroups add up to 6 + 2 + 3 + 4 = 15, the Results report "9 of 15 models (60%)", the Fig. 1 legends say 15 models, and Supplementary Tables S1 and S3 each list the same 15 model IDs. Every model used in the later experiments is one of those 15. Of the two counts, only 15 gives exactly 60% (9/15); with 18 the nearest values are 55.6% (10/18) and 61.1% (11/18), 60% of 18 is 10.8 models, and the 9 responders reported in the Results give 50%. The response rate and the "endpoint met" conclusion hold at 9 of 15. What the abstract gets wrong is the size of the evidence base: it overstates it by 3 models (20%), and it sits in the place readers and meta-analysts most often take sample sizes from.

What the paper reports

Abstract:

Across 18 PDX models undergoing dual inhibition of MEK and CDK4/6, 60% of tumors regressed, meeting the co-clinical trial primary endpoint.

Results, "Combined inhibition of MEK and CDK4/6 in colorectal cancer PDX models", first paragraph:

we evaluated typical RAS models that include a mixture of exon 2 KRASG12/13 (n = 6) P-loop domain mutated PDX models, extended RAS models that include NRASQ61 switch II domain mutated tumors (n = 2) along with KRASA146T nucleotide exchange promoting domain mutated tumors (n = 3; refs. 23, 24), and wild-type RAS tumors (n = 4).

Results, same section, second paragraph:

The PDX co-clinical trial of MEK (trametinib) and CDK4/6 (palbociclib) inhibition met its prespecified primary endpoint of tumor regression of ≥30% in more than 30% of the models. As shown in Fig. 1B and C, the combination of MEK and CDK4/6 inhibition produced ≥30% regression in 9 of 15 models (60%) with significantly greater tumor growth inhibition when compared with single agent–treated PDXs.

Figure 1 legend, panels A to D:

Six PDX models harboring codon 12 or 13 (“typical” RAS), 5 with codons 61 or 149 mutations (“extended” RAS), and 4 wild-type RAS PDX models were analyzed by RPPA

Trametinib (0.25 mpk, daily; green), palbociclib (75 mpk, daily; blue), and their combination (red) were evaluated in 15 mCRC PDX models.

C, Waterfall representation of 15 PDX models’ responses, per PDX model results.

D, Effect of treatments on mice body weight. Right, Tukey plot, after 21 days of treatment. Summarized data for 15 PDX models.

Results, "Mechanisms of acquired resistance":

Intriguingly, elevated phospho-SHP2 level was detected in 11 of 15 PDX models treated with the combination

Materials and Methods, "In vivo studies and PDXs":

PDX model details are provided in Supplementary Table S1.

Discussion, first paragraph:

The co-clinical trial met its primary endpoint of demonstrating tumor regressions in greater than 30% of models

What the paper's own numbers show

Method. I added up the RAS subgroup counts given in the Results text and in the Fig. 1A legend. I then built the list of PDX model IDs from Supplementary Table S1 (sheet "PDX details"), Supplementary Table S3 (the ranking of combination responses, grouped by RAS status), and the Fig. 1B panel titles. I added every model named for the follow-on experiments: the dose study (Fig. 2, Supp. Table S6), the durability cohort (Fig. 4, Supp. Table S7), the SHP2 triple combination (Fig. 5) and Supp. Fig. S2. Last, I checked which denominators can produce the abstract's 60%. Every number below is printed by recompute.py.txt.

Quantity Location Reported Recomputed from the paper's numbers
PDX models given MEK + CDK4/6 inhibition Abstract 18 15; no set of 18 models appears anywhere in the paper or supplement
RAS subgroups, text Results, paragraph 1 n = 6, 2, 3, 4 6 + 2 + 3 + 4 = 15
RAS subgroups, figure legend Fig. 1A legend 6 typical, 5 extended, 4 wild type 6 + 5 + 4 = 15; the text's 2 + 3 = 5 extended models match
Models in the co-clinical trial Results, paragraph 2; Fig. 1B–D legends "9 of 15 models"; "15 mCRC PDX models" 15
Model panels Fig. 1B – 15
Model rows Supp. Table S1 ("PDX details") – 15 unique IDs
Model rows by RAS group Supp. Table S3 – 15 (6 typical, 5 extended, 4 wild type); same IDs as S1 and Fig. 1B
Models in follow-on experiments Figs. 2, 4, 5; Supp. Fig. S2; Supp. Tables S6, S7 3, 8, 2 and 2 models 9 distinct models, 0 outside the 15
All distinct models named anywhere Paper and supplement – 15, so 18 − 15 = 3 models are unaccounted for
Durability cohort Results; Fig. 4 "eight PDX models (4 of each RASmut subtype)" 8, all among the 15 (4 typical, 4 extended)
Regression rate, 15 models Abstract; Results 60%; "9 of 15 models (60%)" 9/15 = 60.0%
Same 9 responders over 18 models – – 9/18 = 50.0%
Responders implied by 60% of 18 Abstract 60% 0.6 × 18 = 10.8, not a whole number; 10/18 = 55.6%, 11/18 = 61.1%
Values of k for which k/n rounds to 60% – – n = 15: k = 9 only; n = 18: none
Primary endpoint (more than 30% of models with ≥30% regression) Results met 9/15 = 60% > 30%. Exact one-sided binomial test against 30% (my calculation; the paper reports no test): P = 0.015. Clopper–Pearson 95% CI 32.3% to 83.7%, one-sided 95% lower bound 36.0%

Figure

The abstract's "18 PDX models" set against the counts of 15 in the Results, the Fig. 1 legends and Supplementary Tables S1 and S3

Figure 1. Two text panels hold short excerpts from the article as archived in PMC. The left panel (orange, the value reported in the abstract) gives the abstract's sentence with its count of 18 models and its 60% response rate. The right panel (blue, counts found in or recomputed from the paper's own body and supplement) gives the Results' "9 of 15 models (60%)", the Results' subgroup counts, which add up to 15, the Fig. 1B legend's "15 mCRC PDX models", and the 15 rows in each of Supplementary Tables S1 and S3. The connector names the conflict: no set of 18 models is described anywhere in the paper, and of the two counts only 15 gives exactly 60% (9/15). The arithmetic is in recompute.py.txt.

Every attainable response rate k/n for n = 15 and n = 18, with the reported 60% marked

Figure 2. Each gray dot is a response rate that can occur with n models (k/n, k = 0 to n), on a full 0–100% axis. The orange vertical line marks the 60% reported in both the abstract and the Results. The dotted line marks the primary endpoint's 30% threshold. With n = 15, 60% falls exactly on 9/15 (filled blue). With n = 18, no attainable value equals 60%: the same 9 responders give 9/18 = 50.0% (filled blue), and the two nearest values are 10/18 = 55.6% and 11/18 = 61.1% (open blue). Of the two counts in the paper, the reported 60% therefore matches the 15-model denominator exactly, and not the 18 stated in the abstract.

Why it matters

The abstract is the only place in the paper that says 18, and the abstract is where readers, indexers and meta-analysts usually take the number of models. Anyone counting PDX models across preclinical studies of MEK plus CDK4/6 inhibition, or citing this study as an example of a co-clinical trial design, would record 3 models (20%) that the paper does not document.

The efficacy conclusion is unaffected. The correct figure is 9 of 15 models with at least 30% regression (60%), well above the prespecified 30% threshold. The exact 95% interval for 9/15 runs from 32.3% to 83.7%. A reader who combined the abstract's 18 with the 9 responders given in the Results would get 50%, which still exceeds the 30% threshold but does not match the abstract's own 60%. The subgroup comparisons (typical vs. extended RAS, TP53, CMS) already rest on small groups, and the 15-model count is the right basis for judging them.

Explanations considered

Status

As of 2026-10-23:

Suggested correction

In the abstract, replace "Across 18 PDX models undergoing dual inhibition of MEK and CDK4/6, 60% of tumors regressed" with "Across 15 PDX models undergoing dual inhibition of MEK and CDK4/6, 9 (60%) regressed". This brings the abstract in line with the Results, the Fig. 1 legends and Supplementary Tables S1 and S3. The journal could also check the Fig. 1A legend's "codons 61 or 149" and the Results' "KRASA146T (n = 3)" against the Fig. 1B panel labels, which show two A146T models and one A146V model.